PharmaTher Achieves Historic Ketamine FDA Approval After Third Attempt
Last reviewed and updated: September 9, 2026.
PharmaTher Holdings Ltd. has secured FDA approval for its ketamine product KETARx, marking the first time the agency has approved a ketamine therapy specifically for surgical pain management. The Toronto based company received approval on August 8, 2025, following two previous rejections that cited minor deficiencies in their application.
Do you work in the ketamine industry? Save thousands on overhead and other fees by joining the first GPO for ketamine clinics and practitioners. There’s no cost to join and zero obligations. Sign up here!
| Key Takeaway | Details |
|---|---|
| Historic Approval | First ketamine product approved for surgical pain management |
| Market Position | First approval for surgical pain management. Generic ketamine has been approved as an anesthetic since 1970 |
| Financial Impact | Shares rose sharply on the approval news in 2025 |
| Market Size | Ketamine remains on the WHO Model List of Essential Medicines |
Breaking the Ketamine Shortage Barrier
Since February 2018, ketamine has been regularly listed on the FDA drug shortage list, creating a significant gap in medical supply. This shortage has forced healthcare providers to rely on compounded ketamine products, which carry safety concerns. The FDA published a compounding risk alert on October 10, 2023, warning about potential risks of compounded ketamine products for psychiatric disorders.
The approval positions PharmaTher to address this critical shortage. CEO Fabio Chianelli emphasized the company’s goal of becoming a leading supplier to fill the U.S. market demand gap.
Market Dynamics and Future Potential
KETARx now competes with Spravato, which analysts estimate will generate $1.4 billion in 2025.
Ketamine stands out among psychedelic drugs as the only one included on the World Health Organization’s Model List of Essential Medicines. This designation underscores its medical importance beyond traditional anesthesia applications.
PharmaTher plans to expand KETARx development into mental health conditions including depression, neurological disorders like Parkinson’s disease, and chronic pain management. The approval provides a foundation for pursuing these additional therapeutic areas through clinical trials, potentially transforming treatment options for patients with complex medical needs.
What the Approval Does and Does Not Cover
This is worth stating plainly, because the coverage around it blurred badly. KETARx is approved for the management of surgical pain. It is not an approval for depression, PTSD, or any psychiatric indication.
It is also not the first FDA-approved ketamine. Racemic ketamine has been approved as an anesthetic since 1970 and is widely marketed as a generic injectable, which is the product ketamine clinics have always used off-label. Spravato, approved in 2019, remains the only ketamine-derived product with a psychiatric indication.
What is genuinely new is the indication and the supply picture. PharmaTher has said it intends to pursue further indications, including complex regional pain syndrome through the 505(b)(2) pathway, and eventually psychiatric and neurological uses. Those are applications yet to be filed or decided, not approvals.
Why Clinics Should Care About Supply
The practical story here is the shortage. Ketamine has appeared on the FDA drug shortage list repeatedly since 2018, and that scarcity is part of why some practices turned to compounded product, which the FDA flagged in a 2023 compounding risk alert.
A newly approved domestic manufacturer entering the market matters more to a clinic’s operations than the indication does. More approved supply means less exposure to shortage-driven pricing and fewer reasons to reach for compounded alternatives. That is the part of this announcement worth watching.
